share_log

UPLOAD: Others

SEC ·  Feb 14 03:46

Summary by Futu AI

The Securities and Exchange Commission (SEC) has notified Cardio Diagnostics that it will not review the company's Form S-3 Registration Statement filed on February 7, 2025. The communication was addressed to CEO Meeshanthini Dogan at the company's Chicago headquarters.The SEC emphasized that the company and its management remain responsible for ensuring the accuracy and adequacy of their disclosures, regardless of the SEC staff's review status, comments, or actions. The decision aligns with standard SEC procedures under Rules 460 and 461 regarding acceleration requests.
The Securities and Exchange Commission (SEC) has notified Cardio Diagnostics that it will not review the company's Form S-3 Registration Statement filed on February 7, 2025. The communication was addressed to CEO Meeshanthini Dogan at the company's Chicago headquarters.The SEC emphasized that the company and its management remain responsible for ensuring the accuracy and adequacy of their disclosures, regardless of the SEC staff's review status, comments, or actions. The decision aligns with standard SEC procedures under Rules 460 and 461 regarding acceleration requests.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 293

Recommended